CClinicalTrials.gg
CompletedNCT03204097Updated Jun 29, 2017

Local Host Modulating Agents Alendronate & Aloe Vera for Treatment of Furcation Defects in Chronic Periodontitis

A Phase 2/3 interventional study of placebo and Alendronate in Chronic Periodontitis, sponsored by Government Dental College and Research Institute, Bangalore. Completed. Open to participants aged 25 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-06-29.

Sponsored by Government Dental College and Research Institute, Bangalore · Phase 2/3, Interventional, and Treatment

Phase
Phase 2/3
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
25 Years to 50 Years
Sex
All
01

Study summary

Alendronate (ALN), commonly use bisphosphonates is proposed to have osteostimulative properties in vivo and in vitro, as shown by an increase in the matrix formation, and acts as a potent inhibitor of bone resorption. AV widely known for its wound healing, analgesic, antioxidant, antibacterial, antiviral, antifungal, immune boosting and significant anti-inflammatory properties. The present study aims to explore the efficacy of 1% ALN and AV gel as a local drug delivery as an adjunct to scaling and root planing (SRP) for the treatment of degree II furcation defects

Read the detailed description

Alendronate (ALN), commonly use bisphosphonates is proposed to have osteostimulative properties in vivo and in vitro, as shown by an increase in the matrix formation, and acts as a potent inhibitor of bone resorption. AV widely known for its wound healing, analgesic, antioxidant, antibacterial, antiviral, antifungal, immune boosting and significant anti-inflammatory properties. The present study aims to explore the efficacy of 1% ALN and AV gel as a local drug delivery as an adjunct to scaling and root planing (SRP) for the treatment of degree II furcation defects.

Methods: Ninety patients with mandibular buccal class II furcation defects were randomly allocated into three treatment groups: SRP plus placebo gel (group 1), SRP plus 1% ALN gel (group 2) and SRP plus AV gel (group3). Clinical and radiographic parameters were recorded at baseline and gel were delivered at respective site. Then again all clinical and radiographic parameters were recorded after 6 and 12 months from baseline.

02

Conditions studied

03

Who can participate

Ages eligible
25 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:Systemically healthy patients with mandibular class II furcation defects and asymptomatic endodontically vital mandibular molars with radiolucency in furcation area with PD ≥ 5mm and horizontal PD ≥ 3mm and with no history of antibiotic or any periodontal therapy in past 6 months were included in the study -

Exclusion Criteria:Subjects with any known systemic disease, allergic to alendronate or aloe vera, on systemic alendronate therapy, alcoholics, tobacco users, pregnant or lactating women

-

04

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
90 participants (actual)

Study arms

  • Placebo comparator
    group 1

    Scaling and root planing (SRP) followed by placebo gel local drug delivery

    Drug: placebo

  • Active comparator
    group 2

    SRP followed by 1% Alendronate (ALN) gel

    Drug: Alendronate

  • Active comparator
    group 3

    SRP followed by Aloevera (AV) gel

    Drug: Aloe Vera

Interventions

  • Drugplacebo

    Oral prophylaxis followed by placement of placebo gel

    Also known as: inactive drug

  • DrugAlendronate

    Oral prophylaxis followed by placement of Alendronate gel

    Also known as: ALN

  • DrugAloe Vera

    Oral prophylaxis followed by placement of Aloe Vera gel

    Also known as: AV

05

What researchers measure

Primary outcomes

  1. Change in Bone defect depth

    Assessed in percentage

    Time frame: baseline, 6 & 12 months

Secondary outcomes

  1. Change in modified sulcus bleeding index

    scale 0-3

    Time frame: baseline, 6 & 12 months

  2. Change in Plaque index

    scale 0-3

    Time frame: baseline, 6 & 12 months

  3. Change in pocket probing depth

    measured in mm

    Time frame: baseline, 6 & 12 months

  4. Change in relative vertical clinical attachment level

    measured in mm

    Time frame: baseline, 6 & 12 months

  5. Change in relative horizontal clinical attachment level

    measured in mm

    Time frame: baseline, 6 & 12 months

06

Study locations

No study locations are listed for this record.

07

Registry details

Key details

Study ID
NCT03204097
Lead sponsor
Government Dental College and Research Institute, Bangalore
Responsible party
Dr. A R Pradeep (Professor and HOD, Dept of Periodontology, Government Dental College and Research Institute, Bangalore) — Principal investigator
First posted
Jun 29, 2017
Start date
Mar 2016
Primary completion
Feb 2017
Completion
Feb 2017
Last update
Jun 29, 2017
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion